Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy.
Kadam AH, Kandasamy K, Buss T, Cederstrom B, Yang C, Narayanapillai S, Rodriguez J, Levin MD, Koziol J, Olenyuk B, Borok Z, Chrastina A, Schnitzer JE.
Kadam AH, et al. Among authors: buss t.
PLoS One. 2022 Nov 22;17(11):e0276462. doi: 10.1371/journal.pone.0276462. eCollection 2022.
PLoS One. 2022.
PMID: 36413536
Free PMC article.